Mirae Asset Global Investments Co., Ltd. Tango Therapeutics, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

$24 Billion
Q4 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 3,580 shares of TNGX stock, worth $7,410. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,580

Previous 3,875 7.61%

Holding current value

$7,410

Previous $29,000 62.07%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 27, 2025	SELL	$2.79 - $7.46 $823 - $2,200	-295 Reduced 7.61%	3,580 $11,000
Q3 2024 Oct 23, 2024	BUY	$7.36 - $11.93 $5,041 - $8,172	685 Added 21.47%	3,875 $29,000
Q2 2024 Jul 30, 2024	SELL	$6.66 - $10.15 $171,654 - $261,606	-25,774 Reduced 88.99%	3,190 $27,000
Q1 2024 May 01, 2024	BUY	$7.51 - $12.88 $53,531 - $91,808	7,128 Added 32.64%	28,964 $229,000
Q4 2023 Jan 24, 2024	BUY	$6.52 - $12.01 $3,051 - $5,620	468 Added 2.19%	21,836 $216,000
Q3 2023 Oct 26, 2023	BUY	$2.93 - $11.26 $231 - $889	79 Added 0.37%	21,368 $240,000
Q2 2023 Aug 10, 2023	SELL	$2.67 - $4.7 $469 - $827	-176 Reduced 0.82%	21,289 $70,000
Q1 2023 May 04, 2023	SELL	$3.76 - $8.06 $210 - $451	-56 Reduced 0.26%	21,465 $84,000
Q4 2022 Feb 09, 2023	BUY	$3.41 - $8.29 $7,607 - $18,494	2,231 Added 11.57%	21,521 $156,000
Q3 2022 Nov 10, 2022	BUY	$3.25 - $5.46 $19,337 - $32,487	5,950 Added 44.6%	19,290 $70,000
Q2 2022 Jul 26, 2022	BUY	$3.86 - $8.01 $51,492 - $106,853	13,340 New	13,340 $60,000

Others Institutions Holding TNGX

# of Institutions

138

Shares Held

91.1M

Call Options Held

1.4K

Put Options Held

4.4K

View Full List

About Tango Therapeutics, Inc.

Ticker TNGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,067,296
Market Cap $182M
Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...

More about TNGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Account

Mirae Asset Global Investments Co., Ltd. Tango Therapeutics, Inc. Transaction History